Annual Net Income
-$41.07 M
-$2.29 M-5.91%
31 December 2023
Summary:
Galectin Therapeutics annual net profit is currently -$41.07 million, with the most recent change of -$2.29 million (-5.91%) on 31 December 2023. During the last 3 years, it has fallen by -$17.60 million (-75.01%). GALT annual net income is now -1203.27% below its all-time high of -$3.15 million, reached on 31 December 2008.GALT Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Net Income
-$11.22 M
+$1.15 M+9.30%
30 September 2024
Summary:
Galectin Therapeutics quarterly net profit is currently -$11.22 million, with the most recent change of +$1.15 million (+9.30%) on 30 September 2024. Over the past year, it has dropped by -$792.00 thousand (-7.59%). GALT quarterly net income is now -297.85% below its all-time high of $5.67 million, reached on 30 September 2006.GALT Quarterly Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM Net Income
-$45.08 M
-$792.00 K-1.79%
30 September 2024
Summary:
Galectin Therapeutics TTM net profit is currently -$45.08 million, with the most recent change of -$792.00 thousand (-1.79%) on 30 September 2024. Over the past year, it has dropped by -$3.37 million (-8.09%). GALT TTM net income is now -10121.54% below its all-time high of -$441.00 thousand, reached on 31 March 2007.GALT TTM Net Income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GALT Net Income Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -5.9% | -7.6% | -8.1% |
| 3 y3 years | -75.0% | -31.7% | -44.7% |
| 5 y5 years | -195.4% | -303.0% | -302.2% |
GALT Net Income High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -75.0% | at low | -55.4% | +9.3% | -47.7% | at low |
| 5 y | 5 years | -208.9% | at low | -303.0% | +9.3% | -302.2% | at low |
| alltime | all time | -1203.3% | at low | -297.9% | +9.3% | <-9999.0% | at low |
Galectin Therapeutics Net Income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$11.22 M(-9.3%) | -$45.08 M(+1.8%) |
| June 2024 | - | -$12.37 M(+7.7%) | -$44.28 M(+7.9%) |
| Mar 2024 | - | -$11.49 M(+14.9%) | -$41.03 M(-0.1%) |
| Dec 2023 | -$41.07 M(+5.9%) | -$10.00 M(-4.1%) | -$41.07 M(-1.5%) |
| Sept 2023 | - | -$10.43 M(+14.4%) | -$41.70 M(+4.6%) |
| June 2023 | - | -$9.11 M(-20.9%) | -$39.87 M(-1.2%) |
| Mar 2023 | - | -$11.53 M(+8.4%) | -$40.37 M(+4.1%) |
| Dec 2022 | -$38.78 M(+27.0%) | -$10.63 M(+23.7%) | -$38.78 M(+9.7%) |
| Sept 2022 | - | -$8.60 M(-10.6%) | -$35.36 M(+0.2%) |
| June 2022 | - | -$9.61 M(-3.2%) | -$35.29 M(+3.4%) |
| Mar 2022 | - | -$9.93 M(+37.5%) | -$34.12 M(+11.8%) |
| Dec 2021 | -$30.53 M(+30.1%) | -$7.22 M(-15.2%) | -$30.53 M(-2.0%) |
| Sept 2021 | - | -$8.52 M(+0.8%) | -$31.16 M(+9.0%) |
| June 2021 | - | -$8.45 M(+33.3%) | -$28.58 M(+8.9%) |
| Mar 2021 | - | -$6.34 M(-19.3%) | -$26.25 M(+11.9%) |
| Dec 2020 | -$23.46 M(+76.5%) | -$7.85 M(+32.1%) | -$23.46 M(+13.1%) |
| Sept 2020 | - | -$5.94 M(-2.8%) | -$20.75 M(+18.0%) |
| June 2020 | - | -$6.11 M(+71.9%) | -$17.59 M(+21.5%) |
| Mar 2020 | - | -$3.56 M(-30.8%) | -$14.47 M(+8.9%) |
| Dec 2019 | -$13.29 M(-4.4%) | -$5.14 M(+84.5%) | -$13.29 M(+18.6%) |
| Sept 2019 | - | -$2.78 M(-7.1%) | -$11.21 M(+0.3%) |
| June 2019 | - | -$3.00 M(+26.2%) | -$11.18 M(-7.0%) |
| Mar 2019 | - | -$2.38 M(-22.1%) | -$12.02 M(-13.5%) |
| Dec 2018 | -$13.90 M(-14.4%) | -$3.05 M(+10.8%) | -$13.90 M(+5.0%) |
| Sept 2018 | - | -$2.75 M(-28.3%) | -$13.23 M(-11.1%) |
| June 2018 | - | -$3.84 M(-9.8%) | -$14.89 M(-4.3%) |
| Mar 2018 | - | -$4.26 M(+78.8%) | -$15.56 M(-4.2%) |
| Dec 2017 | -$16.23 M(-24.3%) | -$2.38 M(-46.0%) | -$16.23 M(-12.0%) |
| Sept 2017 | - | -$4.41 M(-2.2%) | -$18.44 M(-0.6%) |
| June 2017 | - | -$4.51 M(-8.7%) | -$18.56 M(-5.2%) |
| Mar 2017 | - | -$4.94 M(+7.5%) | -$19.57 M(-8.7%) |
| Dec 2016 | -$21.44 M(+7.0%) | -$4.59 M(+1.4%) | -$21.44 M(-0.4%) |
| Sept 2016 | - | -$4.53 M(-18.0%) | -$21.52 M(-5.9%) |
| June 2016 | - | -$5.52 M(-18.8%) | -$22.88 M(+4.0%) |
| Mar 2016 | - | -$6.80 M(+45.6%) | -$22.00 M(+9.9%) |
| Dec 2015 | -$20.03 M(+26.8%) | -$4.67 M(-20.7%) | -$20.03 M(+4.9%) |
| Sept 2015 | - | -$5.89 M(+26.8%) | -$19.09 M(+14.2%) |
| June 2015 | - | -$4.64 M(-3.8%) | -$16.72 M(+7.8%) |
| Mar 2015 | - | -$4.83 M(+29.3%) | -$15.50 M(-1.8%) |
| Dec 2014 | -$15.79 M(+30.6%) | -$3.73 M(+6.1%) | -$15.79 M(+6.3%) |
| Sept 2014 | - | -$3.52 M(+2.6%) | -$14.86 M(-0.2%) |
| June 2014 | - | -$3.43 M(-32.9%) | -$14.88 M(+6.3%) |
| Mar 2014 | - | -$5.11 M(+82.6%) | -$13.99 M(+15.8%) |
| Dec 2013 | -$12.09 M(+24.9%) | -$2.80 M(-21.0%) | -$12.09 M(+3.6%) |
| Sept 2013 | - | -$3.54 M(+39.2%) | -$11.66 M(+7.9%) |
| June 2013 | - | -$2.54 M(-20.6%) | -$10.81 M(-1.1%) |
| Mar 2013 | - | -$3.20 M(+34.8%) | -$10.93 M(+13.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2012 | -$9.68 M(-11.4%) | -$2.38 M(-11.6%) | -$9.68 M(-9.3%) |
| Sept 2012 | - | -$2.69 M(+1.1%) | -$10.67 M(+6.6%) |
| June 2012 | - | -$2.66 M(+36.4%) | -$10.01 M(-4.5%) |
| Mar 2012 | - | -$1.95 M(-42.1%) | -$10.47 M(-4.0%) |
| Dec 2011 | -$10.91 M(+93.9%) | -$3.37 M(+66.1%) | -$10.91 M(+31.9%) |
| Sept 2011 | - | -$2.03 M(-35.1%) | -$8.28 M(+12.5%) |
| June 2011 | - | -$3.13 M(+30.7%) | -$7.36 M(+25.0%) |
| Mar 2011 | - | -$2.39 M(+228.6%) | -$5.88 M(+4.5%) |
| Dec 2010 | -$5.63 M(-24.6%) | -$728.00 K(-34.4%) | -$5.63 M(+1.3%) |
| Sept 2010 | - | -$1.11 M(-33.0%) | -$5.56 M(-4.5%) |
| June 2010 | - | -$1.65 M(-22.6%) | -$5.82 M(-17.0%) |
| Mar 2010 | - | -$2.14 M(+226.4%) | -$7.00 M(-6.1%) |
| Dec 2009 | -$7.46 M(+136.8%) | -$655.00 K(-52.2%) | -$7.46 M(-2.1%) |
| Sept 2009 | - | -$1.37 M(-51.8%) | -$7.62 M(+26.2%) |
| June 2009 | - | -$2.84 M(+9.6%) | -$6.04 M(+60.6%) |
| Mar 2009 | - | -$2.60 M(+218.0%) | -$3.76 M(+19.3%) |
| Dec 2008 | -$3.15 M(-66.6%) | -$816.00 K(-481.3%) | -$3.15 M(-13.5%) |
| Sept 2008 | - | $214.00 K(-138.0%) | -$3.64 M(-43.5%) |
| June 2008 | - | -$563.00 K(-71.7%) | -$6.44 M(+10.2%) |
| Mar 2008 | - | -$1.99 M(+51.7%) | -$5.84 M(-38.0%) |
| Dec 2007 | -$9.43 M(+195.4%) | -$1.31 M(-49.4%) | -$9.43 M(+6.1%) |
| Sept 2007 | - | -$2.59 M(-7283.3%) | -$8.89 M(+1300.3%) |
| June 2007 | - | $36.00 K(-100.6%) | -$635.00 K(+44.0%) |
| Mar 2007 | - | -$5.57 M(+625.8%) | -$441.00 K(-79.7%) |
| Dec 2006 | -$3.19 M(-51.2%) | -$768.00 K(-113.5%) | -$2.18 M(-31.1%) |
| Sept 2006 | - | $5.67 M(+2365.7%) | -$3.16 M(-70.0%) |
| June 2006 | - | $230.00 K(-103.1%) | -$10.51 M(-15.5%) |
| Mar 2006 | - | -$7.31 M(+317.9%) | -$12.44 M(+90.0%) |
| Dec 2005 | -$6.54 M(-8.9%) | -$1.75 M(+4.1%) | -$6.54 M(-5.9%) |
| Sept 2005 | - | -$1.68 M(-1.1%) | -$6.95 M(-1.2%) |
| June 2005 | - | -$1.70 M(+19.8%) | -$7.04 M(+4.3%) |
| Mar 2005 | - | -$1.42 M(-34.3%) | -$6.74 M(-6.1%) |
| Dec 2004 | -$7.18 M(+47.3%) | -$2.16 M(+22.4%) | -$7.18 M(+8.9%) |
| Sept 2004 | - | -$1.76 M(+25.5%) | -$6.59 M(+6.1%) |
| June 2004 | - | -$1.41 M(-24.2%) | -$6.21 M(+7.4%) |
| Mar 2004 | - | -$1.85 M(+18.0%) | -$5.78 M(+18.7%) |
| Dec 2003 | -$4.87 M(+32.5%) | -$1.57 M(+13.6%) | -$4.87 M(+10.2%) |
| Sept 2003 | - | -$1.38 M(+41.9%) | -$4.42 M(+19.4%) |
| June 2003 | - | -$974.60 K(+3.1%) | -$3.70 M(+0.9%) |
| Mar 2003 | - | -$944.90 K(-15.6%) | -$3.67 M(-0.2%) |
| Dec 2002 | -$3.68 M(-7.4%) | -$1.12 M(+68.8%) | -$3.68 M(-26.6%) |
| Sept 2002 | - | -$663.60 K(-29.6%) | -$5.01 M(-0.5%) |
| June 2002 | - | -$942.40 K(-1.0%) | -$5.04 M(+7.3%) |
| Mar 2002 | - | -$952.30 K(-61.2%) | -$4.69 M(+25.5%) |
| Dec 2001 | -$3.97 M | -$2.46 M(+257.9%) | -$3.74 M(+191.2%) |
| Sept 2001 | - | -$686.30 K(+14.7%) | -$1.28 M(+114.7%) |
| June 2001 | - | -$598.10 K | -$598.10 K |
FAQ
- What is Galectin Therapeutics annual net profit?
- What is the all time high annual net income for Galectin Therapeutics?
- What is Galectin Therapeutics annual net income year-on-year change?
- What is Galectin Therapeutics quarterly net profit?
- What is the all time high quarterly net income for Galectin Therapeutics?
- What is Galectin Therapeutics quarterly net income year-on-year change?
- What is Galectin Therapeutics TTM net profit?
- What is the all time high TTM net income for Galectin Therapeutics?
- What is Galectin Therapeutics TTM net income year-on-year change?
What is Galectin Therapeutics annual net profit?
The current annual net income of GALT is -$41.07 M
What is the all time high annual net income for Galectin Therapeutics?
Galectin Therapeutics all-time high annual net profit is -$3.15 M
What is Galectin Therapeutics annual net income year-on-year change?
Over the past year, GALT annual net profit has changed by -$2.29 M (-5.91%)
What is Galectin Therapeutics quarterly net profit?
The current quarterly net income of GALT is -$11.22 M
What is the all time high quarterly net income for Galectin Therapeutics?
Galectin Therapeutics all-time high quarterly net profit is $5.67 M
What is Galectin Therapeutics quarterly net income year-on-year change?
Over the past year, GALT quarterly net profit has changed by -$792.00 K (-7.59%)
What is Galectin Therapeutics TTM net profit?
The current TTM net income of GALT is -$45.08 M
What is the all time high TTM net income for Galectin Therapeutics?
Galectin Therapeutics all-time high TTM net profit is -$441.00 K
What is Galectin Therapeutics TTM net income year-on-year change?
Over the past year, GALT TTM net profit has changed by -$3.37 M (-8.09%)